Most Recent Articles by Florence Chaverneff, PhD
Eptinezumab has shown 100% bioavailability when administered intravenously.
Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.
Individuals with chronic migraine may present with age-related changes in cortical thickness.
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Eptinezumab, a humanized monoclonal antibody specific to calcitonin gene-related peptide, may be an effective prophylactic for individuals with frequent episodic migraines.
More Articles by Florence Chaverneff, PhD
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Identifying Intracranial Hypertension in Children: Added Challenges
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Insurance Status Tied to Higher Self-Perceived Poor/Fair Health
- Early Treatment Failure More Likely With Carbamazepine vs Lamotrigine in Epilepsy
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Concurrent Non-Motor Functions Strongly Associated With Parkinson Disease
- Feeling Young May Be Reflected in Brain Structure